The business case for bariatric surgery revisited: a non-randomized case-control study

Area of Science:

• Bariatric Surgery Outcomes
• Health Economics
• Medical Claims Analysis

Background:

• Previous studies suggested bariatric surgery (LAGB, LRYGB) is cost-saving.
• These studies often used comparison groups with morbid obesity (MO) diagnosis codes.
• This may not accurately reflect patients undergoing these procedures.

Purpose of the Study:

• To re-estimate the net costs and breakeven time for bariatric surgery.
• To use an alternative comparison sample not restricted to MO diagnosis codes.

Main Methods:

• Non-randomized case-control study utilizing US commercial medical claims data.
• Propensity score matching of LAGB and LRYGB patients to two control groups: one with MO codes, one without.
• Analysis of cost recovery and net savings over time.

Main Results:

• When excluding MO diagnosis codes, LAGB breakeven extends to 5.25 years with a 5-year net cost of $690.
• LRYGB breakeven exceeds 10 years with a 5-year net cost of $18,940.
• These findings contrast with prior studies using MO-restricted samples.

Conclusions:

• Bariatric surgery's net costs and breakeven times are likely less favorable than previously reported.
• LRYGB shows a significantly longer breakeven period compared to LAGB.
• Study highlights the impact of comparison group selection on cost-effectiveness analysis.